Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lixte Biotechnology Holdings (LIXT) Cash & Equivalents (2016)

Lixte Biotechnology Holdings' Cash & Equivalents history spans 5 years, with the latest figure at $669771.0 for Q3 2016.

  • For Q3 2016, Cash & Equivalents rose 207.86% year-over-year to $669771.0; the TTM value through Sep 2016 reached $669771.0, up 207.86%, while the annual FY2015 figure was $25281.0, N/A changed from the prior year.
  • Cash & Equivalents reached $669771.0 in Q3 2016 per LIXT's latest filing, up from $95776.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.7 million in Q4 2012 to a low of $8864.0 in Q3 2014.
  • Average Cash & Equivalents over 5 years is $461101.1, with a median of $140101.0 recorded in 2015.
  • Peak YoY movement for Cash & Equivalents: tumbled 98.88% in 2014, then surged 2354.39% in 2015.
  • A 5-year view of Cash & Equivalents shows it stood at $1.7 million in 2012, then plummeted by 71.3% to $475019.0 in 2013, then tumbled by 98.13% to $8864.0 in 2014, then skyrocketed by 185.21% to $25281.0 in 2015, then surged by 2549.31% to $669771.0 in 2016.
  • Per Business Quant, the three most recent readings for LIXT's Cash & Equivalents are $669771.0 (Q3 2016), $95776.0 (Q2 2016), and $99386.0 (Q1 2016).